![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
This visual helps illustrate the nuances of each type of bagging in specialty pharmacy and what it may mean for your health system.
Good News for Biosimilar Adoption Rates as Pharmacies Find Workable Strategies
Navigating the use of biosimilars with the 340B Drug Pricing Program.
By
Date
January 11, 2022
Read time: 7 minutes
After a slow start, biosimilar adoption rates are trending upward in the United States. According to AmGen, there was a 65% increase in the number of approved biosimilars between 2019-2020 and a 157% increase in available biosimilars in the U.S.
An expert from our 340B Solutions team explains what these biosimilar adoption rates mean for 340B-qualified pharmacies.
Learn more about navigating the use of biosimilars with the 340B Drug Pricing Program.
Related Stories
As strategic partners, our Specialty Pharmacy Enablement experts can help drive improvements across the board.
In a unique, retreat-style setting, health systems leaders had close conversations around best practices, wins, struggles, and solutions.
Industry event highlights how connection, creativity, and a fresh perspective are shaping the future of health system innovation.
The top three Prescribed Perspectives articles downloaded by health systems in May.
An exclusive introduction to our newest services and solutions designed to help forward-thinking health systems modernize their specialty and infusion strategies.
As the infusion services market continues to evolve and challenge one of health systems’ longstanding service lines – new opportunities are also emerging.
Drug shortages have decreased, but supply chain complexity requires ongoing innovation and resilience to maintain drug availability.
The top three Prescribed Perspectives articles downloaded by health systems in March.
Integrated health system specialty pharmacies improve medication access, enhance treatment plan adherence, and support better outcomes.